Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1660-1667

  Andrésdóttir, Gudbjörg ^a   Jensen, Majken L ^a   Carstensen, Bendix ^a   Parving, Hans Henrik ^b,c,d   Rossing, Kasper ^b   Hansen, Tine W ^a   Rossing, Peter ^a,c,d  

^a STENO DIABETES CENTER   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; RENIN INHIBITOR;

ADULT; ALBUMINURIA; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; MULTISTATE MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONBIOLOGICAL MODEL; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SURVIVAL RATE; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; FOLLOW UP; KIDNEY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; ALBUMINURIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84901450202     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2036     Document Type: Article

References (40)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229-234
2. Tonelli M, Muntner P, Lloyd A, et al.; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380:807-814
3. Gerstein HC,Mann JF, Yi Q, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286: 421-426
4. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int 1982;21:730-738
5. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501
6. Kussman MJ, Goldstein H, Gleason RE. The clinical course of diabetic nephropathy. JAMA 1976;236:1861-1863
7. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM.diabetes 1995;44:1303-1309
8. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1:1175-1179
9. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982;285: 685-688
10. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
11. Gaede P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348: 383-393
12. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
13. Brenner BM, CooperME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
14. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
15. Forsblom C, Harjutsalo V, Thorn LM, et al.; FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011;22:537-544
16. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004;66:1596-1605
17. Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972;30:271-274
18. Christensen PK, Lund S, Parving HH. The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes. Scand J Clin Lab Invest 2001;61:43-50
19. Carrillo S. Updated information for IDMS traceable VITROS chemistry products CREA slides, 2008. Rochester, NY, Ortho Clinical Diagnostics. Available from http://clincalc.com/Downloads/OrthoClinicalDiagnostics-IDMS-20080612.pdf. Accessed 27 December 2013
20. Carstensen B, Plummer M. Using Lexis objects for multi-state models in R. J Stat Softw 2011;38:1-18
21. Plummer M, Carstensen B. Lexis: An R class for epidemiological studies with long-term follow-up. J Stat Softw 2011;38:1-12
22. R Development Core Team. R: A Language and Environment for Statistical Computing. 2011. Vienna, Austria, R Foundation for Statistical Computing. Available from http://www.R-project.org/. Accessed 1 October 2013
23. Sørensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 2006;70:187-191
24. Danish Nephrology Registry Annual Report 2011. Danish Society of Nephrology. Available from http://www.nephrology.dk/Publikationer/Landsregister/ %C3%85rsrapport%202011.pdf. Accessed 3 May 2013 [in Danish]
25. Danish Health and Medicines Authority. The Danish National Diabetes Register 2007. Nye tal fra Sundhedsstyrelsen 2009;13:1-9 [in Danish]
26. Williams ME. Diabetic CKD/ESRD 2010: a progress report? Semin Dial 2010;23:129-133
27. Comas J, Arcos E, Castell C, et al. Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia. Nephrol Dial Transplant 2013;28:1191-1198
28. Parving H-H, Mauer M, Fioretto P, Rossing P, Ritz E. Diabetic nephropathy. In Brenner and Rector: The KIDNEY. Taal MW, Ed. Philadelphia, Elsevier, 2012, p. 1411-1454
29. Nelson RG, Bennett PH, Beck GJ, et al.; Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996;335:1636-1642
30. Yokoyama H, Kanno S, Takahashi S, et al. Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes. Nephrol Dial Transplant 2011; 26:2924-2930
31. Babazono T, Nyumura I, Toya K, et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care 2009;32:1518-1520
32. Unsal A, Koc Y, Basturk T, Akgun AO, Sakaci T, Ahbap E. Risk factors for progression of renal disease in patient with diabetic nephropathy. Eur Rev Med Pharmacol Sci 2012;16:878-883
33. Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA. Progression of kidney disease in type 2 diabetes -beyond blood pressure control: an observational study. BMC Nephrol 2005; 6:8
34. Rossing P, Rossing K, Gaede P, Pedersen O, Parving HH. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 2006;29: 1024-1030
35. Gaspari F, Ruggenenti P, Porrini E, et al.; GFR Study Investigators. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013;84:164-173
36. Bakris GL, Weir MR, Shanifar S, et al.; RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-1565
37. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377: 2181-2192
38. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317: 713-720
39. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006;69: 913-919
40. Rossing P, Parving H-H, de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy-fact or fiction? Nephrol Dial Transplant 2006;21:2354-2357